Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/mechanisms-of-resistance-to-egfr-tyrosine-kinase-inhibitors-xdK3cyeYPj
References (79)
-
N. Godin-Heymann, Ianthe Bryant, M. Rivera, L. Ulkus, D. Bell, D. Riese, J. Settleman, D. Haber (2007)
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.Cancer research, 67 15
-
P. Broermann, K. Junker, Burkhard Brandt, A. Heinecke, L. Freitag, F. Klinke, W. Berdel, Michael Thomas (2002)
Trimodality treatment in Stage III nonsmall cell lung carcinomaCancer, 94
-
J. Mendelsohn, J. Baselga (2003)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
-
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
-
B. Fuchs, T. Fujii, J. Dorfman, Jonathan Goodwin, A. Zhu, M. Lanuti, K. Tanabe (2008)
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.Cancer research, 68 7
-
G. Giannelli, N. Napoli, S. Antonaci (2007)
Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma.Current pharmaceutical design, 13 32
-
Florence Calvez, A. Mukeria, J. Hunt, Olaf Kelm, R. Hung, P. Tanière, P. Brennan, P. Boffetta, D. Zaridze, P. Hainaut (2005)
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.Cancer research, 65 12
-
F. Cappuzzo, L. Toschi, G. Tallini, G. Ceresoli, I. Domenichini, S. Bartolini, G. Finocchiaro, E. Magrini, G. Metro, A. Cancellieri, R. Trisolini, L. Crinò, P. Bunn, A. Santoro, W. Franklin, M. Varella-Garcia, F. Hirsch (2006)
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.Annals of oncology : official journal of the European Society for Medical Oncology, 17 7
-
L. Sequist, T. Lynch (2008)
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Annual review of medicine, 59
-
Amit Kumar, E. Petri, B. Halmos, T. Boggon (2008)
Structure and clinical relevance of the epidermal growth factor receptor in human cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
-
C. Yun, Kristen Mengwasser, A. Toms, M. Woo, H. Greulich, Kwok-kin Wong, M. Meyerson, M. Eck (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 105
-
E. Buck, A. Eyzaguirre, J. Haley, N. Gibson, P. Cagnoni, K. Iwata (2006)
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivityMolecular Cancer Therapeutics, 5
-
J. Thiery (2003)
Epithelial-mesenchymal transitions in development and pathologies.Current opinion in cell biology, 15 6
-
S. Benvenuti, P. Comoglio (2007)
The MET receptor tyrosine kinase in invasion and metastasisJournal of Cellular Physiology, 213
-
Chang-Qi Zhu, G. Santos, K. Ding, A. Sakurada, J. Cutz, Ni Liu, Tong Zhang, P. Marrano, M. Whitehead, J. Squire, S. Kamel‐Reid, L. Seymour, F. Shepherd, M. Tsao (2008)
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 26
-
H. Sasaki, K. Endo, M. Takada, M. Kawahara, N. Kitahara, Hisaichi Tanaka, M. Okumura, A. Matsumura, K. Iuchi, T. Kawaguchi, O. Kawano, H. Yukiue, T. Yokoyama, M. Yano, Y. Fujii (2007)
EGFR exon 20 insertion mutation in Japanese lung cancer.Lung cancer, 58 3
-
N. Normanno, A. Luca, C. Bianco, L. Strizzi, M. Mancino, M. Maiello, A. Carotenuto, G. Feo, F. Caponigro, D. Salomon (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer.Gene, 366 1
-
M. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. Rao, C. Sawyers (2001)
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 293
-
R. Mulloy, A. Ferrand, Youngjo Kim, Raffaella Sordella, D. Bell, D. Haber, K. Anderson, J. Settleman (2007)
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.Cancer research, 67 5
-
T. Kim, J. Murren (2002)
Erlotinib OSI/Roche/Genentech.Current opinion in investigational drugs, 3 9
-
Atsuko Ogino, H. Kitao, Seiki Hirano, A. Uchida, M. Ishiai, T. Kozuki, N. Takigawa, M. Takata, K. Kiura, M. Tanimoto (2007)
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.Cancer research, 67 16
-
P Broermann, K Junker, BH Brandt (2002)
Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapyCancer, 94
-
S. Siena, Marc Peeters, E. Cutsem, Yves Humblet, Pierfranco Conte, Emilio Bajetta, D. Comandini, G. Bodoky, G. Hazel, T. Šálek, Michael Wolf, G. Devercelli, M. Woolley, R. Amado (2007)
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumabBritish Journal of Cancer, 97
-
A. Chakravarti, J. Loeffler, N. Dyson (2002)
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.Cancer research, 62 1
-
Michael Huncharek, Joshua Muscat, J. Geschwind (1999)
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.Carcinogenesis, 20 8
-
J. Engelman, P. Jänne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B. Johnson, L. Cantley (2005)
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Proceedings of the National Academy of Sciences of the United States of America, 102 10
-
H. Jones, L. Goddard, J. Gee, S. Hiscox, Michele Rubini, D. Barrow, J. Knowlden, Sophie Williams, A. Wakeling, R. Nicholson (2004)
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.Endocrine-related cancer, 11 4
-
F. Morgillo, J. Woo, Edward Kim, W. Hong, Ho-Yyoung Lee (2006)
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.Cancer research, 66 20
-
E. Penuel, G. Schaefer, R. Akita, M. Sliwkowski (2001)
Structural requirements for ErbB2 transactivation.Seminars in oncology, 28 6 Suppl 18
-
R. Roskoski (2004)
The ErbB/HER receptor protein-tyrosine kinases and cancer*1Biochemical and Biophysical Research Communications, 319
-
J. Moyer, E. Barbacci, K. Iwata, L. Arnold, B. Boman, A. Cunningham, Catherine DiOrio, Jonathan Doty, M. Morin, M. Moyer, M. Neveu, V. Pollack, L. Pustilnik, M. Reynolds, D. Sloan, A. Theleman, P. Miller (1997)
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.Cancer research, 57 21
-
Y. Yarden (2001)
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.European journal of cancer, 37 Suppl 4
-
S. Thomson, E. Buck, F. Petti, Graeme Griffin, E. Brown, Nishal Ramnarine, K. Iwata, N. Gibson, J. Haley (2005)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.Cancer research, 65 20
-
Joyce Bos (1989)
ras oncogenes in human cancer: a review.Cancer research, 49 17
-
Y. Yarden, M. Sliwkowski (2001)
Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2
-
M. Lemmon, Z. Bu, J. Ladbury, Min Zhou, D. Pinchasi, I. Lax, D. Engelman, J. Schlessinger (1997)
Two EGF molecules contribute additively to stabilization of the EGFR dimerThe EMBO Journal, 16
-
A. Levitzki (2003)
EGF receptor as a therapeutic target.Lung cancer, 41 Suppl 1
-
S. Soltoff, K. Carraway, S. Prigent, W. Gullick, L. Cantley (1994)
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factorMolecular and Cellular Biology, 14
-
M. Guix, A. Faber, S. Wang, M. Olivares, Youngchul Song, S. Qu, C. Rinehart, B. Seidel, D. Yee, C. Arteaga, J. Engelman (2008)
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.The Journal of clinical investigation, 118 7
-
R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. Ratzkin, M. Sela, Y. Yarden (1996)
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.The EMBO Journal, 15
-
J. Engelman, T. Mukohara, K. Zejnullahu, E. Lifshits, A. Borras, Christopher-Michael Gale, G. Naumov, B. Yeap, E. Jarrell, J. Sun, Sean Tracy, Xiaojun Zhao, J. Heymach, B. Johnson, L. Cantley, P. Jänne (2006)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.The Journal of clinical investigation, 116 10
-
H. Shigematsu, A. Gazdar (2006)
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 118
-
S. Barr, S. Thomson, E. Buck, S. Russo, F. Petti, Izabela Sujka-Kwok, A. Eyzaguirre, Maryland Rosenfeld-Franklin, N. Gibson, M. Miglarese, D. Epstein, K. Iwata, J. Haley (2008)
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitionsClinical & Experimental Metastasis, 25
-
M. Mano, Y. Humblet (2008)
Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancerNature Clinical Practice Oncology, 5
-
P. Guy, J. Platko, Lewis CANTLEYt, R. Cerione, K. IIItt (1994)
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.Proceedings of the National Academy of Sciences of the United States of America, 91 17
-
C. Desbois-Mouthon, W. Cacheux, M. Eggelpoël, V. Barbu, L. Fartoux, R. Poupon, C. Housset, O. Rosmorduc (2006)
Impact of IGF‐1R/EGFR cross‐talks on hepatoma cell sensitivity to gefitinibInternational Journal of Cancer, 119
-
M. Balak, Y. Gong, Gregory Riely, R. Somwar, Allan Li, M. Zakowski, Anne Chiang, Guangli Yang, O. Ouerfelli, M. Kris, M. Ladanyi, V. Miller, W. Pao (2006)
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase InhibitorsClinical Cancer Research, 12
-
M. Kraus, W. Issing, T. Miki, Nicholas POPESCUt, S. Aaronson (1989)
Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.Proceedings of the National Academy of Sciences of the United States of America, 86 23
-
John Johnson, M. Cohen, R. Sridhara, Yeh-Fong Chen, G. Williams, J. Duan, J. Gobburu, B. Booth, K. Benson, J. Leighton, L. Hsieh, N. Chidambaram, P. Zimmerman, R. Pazdur (2005)
Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy RegimenClinical Cancer Research, 11
-
R. Amado, M. Wolf, M. Peeters, E. Cutsem, S. Siena, Daniel Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. Patterson, David Chang (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
-
E. Cutsem, I. Láng, G. D'Haens, V. Moiseyenko, J. Zaluski, G. Folprecht, S. Tejpar, O. Kisker, C. Stroh, P. Rougier (2008)
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experienceJournal of Clinical Oncology, 26
-
James Lee, E. Chu (2007)
First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.Clinical colorectal cancer, 6 Suppl 2
-
S. Blencke, A. Ullrich, H. Daub (2003)
Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors*The Journal of Biological Chemistry, 278
-
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
-
M. Mazzone, P. Comoglio (2006)
The Met pathway: master switch and drug target in cancer progressionThe FASEB Journal, 20
-
M. Sattler, R. Salgia (2007)
c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapyCurrent Oncology Reports, 9
-
E. Buck, A. Eyzaguirre, S. Barr, S. Thompson, R. Sennello, David Young, K. Iwata, N. Gibson, P. Cagnoni, J. Haley (2007)
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibitionMolecular Cancer Therapeutics, 6
-
E. Buck, A. Eyzaguirre, Maryland Rosenfeld-Franklin, S. Thomson, M. Mulvihill, S. Barr, E. Brown, M. O'Connor, Yan Yao, J. Pachter, M. Miglarese, D. Epstein, K. Iwata, J. Haley, N. Gibson, Q. Ji (2008)
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.Cancer research, 68 20
-
M. Tsao, C. Zhu, A. Sakurada, T. Zhang, M. Whitehead, S. Kamel‐Reid, K. Ding, L. Seymour, F. Shepherd (2006)
An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
D. Riese, Richard Gallo, J. Settleman (2007)
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesisBioEssays, 29
-
A. Minn, G. Gupta, P. Siegel, Paula Bos, Weiping Shu, D. Giri, A. Viale, A. Olshen, W. Gerald, J. Massagué (2005)
Genes that mediate breast cancer metastasis to lungNature, 436
-
Bram Craene, B. Gilbert, C. Stove, E. Bruyneel, F. Roy, G. Berx (2005)
The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program.Cancer research, 65 14
-
W. Pao, V. Miller, K. Politi, Gregory Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus (2005)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2
-
R. Roskoski (2004)
The ErbB/HER receptor protein-tyrosine kinases and cancer.Biochemical and biophysical research communications, 319 1
-
G. Plowman, G. Whitney, M. Neubauer, Janell Green, V. McDonald, G. Todaro, M. Shoyab, Oncogen (1990)
Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.Proceedings of the National Academy of Sciences of the United States of America, 87 13
-
S. Thomson, F. Petti, Izabela Sujka-Kwok, D. Epstein, J. Haley (2008)
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancyClinical & Experimental Metastasis, 25
-
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 316
-
E. Buck, A. Eyzaguirre, S. Thomson, S. Barr, M. Miglarese, J. Haley, K. Iwata (2007)
Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascadeMolecular Cancer Therapeutics, 6
-
J. Bean, C. Brennan, J. Shih, Gregory Riely, A. Viale, Lu Wang, D. Chitale, N. Motoi, J. Szőke, S. Broderick, M. Balak, Wen‐Cheng Chang, Chong-Jen Yu, Adi Gazdar, H. Pass, V. Rusch, W. Gerald, Shiu-Feng Huang, Pan‐Chyr Yang, V. Miller, M. Ladanyi, Chih‐Hsin Yang, W. Pao (2007)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 104
-
M. Moore, D. Goldstein, J. Hamm, A. Figer, J. Hecht, S. Gallinger, H. Au, P. Murawa, D. Walde, R. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, Mieke Ptasynski, W. Parulekar (2023)
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 41
-
M. Inukai, S. Toyooka, Sachio Ito, Hiroaki Asano, Shuji Ichihara, J. Soh, Hiroshi Suehisa, M. Ouchida, K. Aoe, M. Aoe, K. Kiura, N. Shimizu, H. Date (2006)
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.Cancer research, 66 16
-
J. Lafky, J. Wilken, A. Baron, N. Maihle (2008)
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.Biochimica et biophysica acta, 1785 2
-
R. Yauch, T. Januario, D. Eberhard, G. Cavet, Wenjing Zhu, L. Fu, Thinh Pham, R. Soriano, Jeremy Stinson, S. Seshagiri, Z. Modrušan, Chine-Yu Lin, V. O'Neill, L. Amler (2005)
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer PatientsClinical Cancer Research, 11
-
M. Burgess, B. Skaggs, N. Shah, F. Lee, C. Sawyers (2005)
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.Proceedings of the National Academy of Sciences of the United States of America, 102 9
-
Raffaella Sordella, D. Bell, D. Haber, J. Settleman (2004)
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 305
-
C. Eng (2008)
K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer.Clinical advances in hematology & oncology : H&O, 6 3
-
S. Ahrendt, P. Decker, Enas Alawi, Yong‐ran Zhu, M. Sanchez-Cespedes, Stephen Yang, G. Haasler, A. Kajdacsy‐Balla, M. Demeure, D. Sidransky (2001)
Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lungCancer, 92
-
Hong-Hee Kim, U. Vijapurkar, N. Hellyer, Dolores Bravo, J. Koland (1998)
Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein.The Biochemical journal, 334 ( Pt 1)
-
K. Carraway, M. Sliwkowski, R. Akita, J. Platko, P. Guy, A. Nuijens, A. Diamonti, R. Vandlen, L. Cantley, R. Cerione (1994)
The erbB3 gene product is a receptor for heregulin.The Journal of biological chemistry, 269 19
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by The Author(s)
- Subject
- Medicine & Public Health; Biomedicine general; Oncology
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-008-0093-6
- Publisher site
- See Article on Publisher Site
Abstract
The receptor for epidermal growth factor (EGFR, ErbB1, HER1) supports the growth and maintenance of a broad range of human tumor types, and EGFR-targeting drugs are approved for the treatment of several advanced stage cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, squamous cell cancer of the head and neck (SCCHN), and colorectal cancer. Recent years have witnessed significant advances in our understanding of dysregulated signal transduction in cancer cells resulting from changes in the expression and/or mutational status of key signaling molecules that modulate sensitivity to drugs targeting EGFR. Based on this knowledge, we have an exciting opportunity to maximize the benefit provided to cancer patients by EGFR inhibitors. In this review article, we describe molecular determinants of sensitivity or resistance to EGFR-targeted agents, with specific emphasis on EGFR tyrosine kinase inhibitors (TKIs). The impact of these findings on our ability to evaluate candidate predictive biomarkers and to design robust mechanism-based combination strategies is also discussed.
Journal
Targeted Oncology – Springer Journals
Published: Oct 24, 2008